Shots:
- Avant Technologies and Austrianova signed a joint venture and licensing agreement to form Klothonova, a 50/50 Nevada-based Joint Venture focused on developing cell-based therapies using encapsulated Klotho-producing cells
- Under the terms of the agreement, Klothonova will leverage Austrianova’s proprietary cell-encapsulation technology to develop and commercialize therapies for Alzheimer’s disease, heart disease, cancer, kidney disease, other age-related conditions, and longevity promotion
- Furthermore, Austrianova will provide intellectual property and its expertise in cell biology & GMP-grade encapsulated cell products; Avant will provide capital and operational support to drive Klothonova’s pipeline development
Ref: PRNewsWire| Image: Avant Technologies and Austrianova | Press Release
Related News:- VectorY Therapeutics Collaborates with Shape Therapeutics to Develop Vectorized Antibodies for Neurodegenerative Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
